Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Libby CJ, Gc S, Benavides GA, et al
Why this trial matters: First bispecific + CD38 combo to show superior PFS and OS in Phase III in RRMM Potential new standard of care as early as second-line Demonstrates deep responses, high MRD-negativity, and durable outcomes First-line Strategies in BRAF V600E-Mutant mCRC: Real-World Evidence Signals Treatment Priorities In a real-world retrospective cohort of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), frontline chemotherapy plus anti-VEGF therapy was associated with the longest survival outcomes, while BRAF-targeted strategies showed promising response rates, emphasizing the need for tailored therapy and prospective validation
Weeks 24: This is when most people start to see changes in their skin or more consistent energy levels throughout the day
10.1152/physrev.00034.2006 4
.jpg)
